Ruxolitinib prescription in myelofibrosis

被引：0
|
作者：
Lemal, Richard [1 ]
Robin, Marie [2 ]
Ravinet, Aurelie [1 ]
Cacheux, Victoria [1 ]
Guieze, Romain [1 ]
Bay, Jacques-Olivier [1 ]
机构：
[1] Univ Auvergne, Serv Hematol Clin Adulte & Therapie Cellulaire, CHU Clermont Ferrand, CHU Estaing,CREaT EA 7283,Inserm,CIC 501, F-63000 Clermont Ferrand, France
[2] Hop St Louis, AP HP, Serv Hematol Greffe, F-75010 Paris, France
来源：
BULLETIN DU CANCER | 2013年 / 100卷 / 09期
关键词：
ruxolitinib; primary myelofibrosis; myeloproliferative syndrome; splenomegaly; JAK2; INHIBITOR; INCB018424; PHARMACOKINETICS; TRANSPLANTATION; EFFICACY; SAFETY;
D O I：
10.1684/bdc.2013.1792
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ruxolitinib is a JAK/STAT inhibitor, which has demonstrated clinical benefits in patients with intermediate-2 and high-risk myelofibrosis. Moreover, first results of recent clinical trials show a trend to better overall survival with ruxolitinib, which allows to hope that we will soon be able to change the natural evolution of this poor outcome disease. With such results, ruxolitinib quickly obtained the Food and Drug Administration (FDA) approval in the United States of America. In France, ruxolitinib is now available, allowing its administration to symptomatic myelofibrosis patients.
引用
收藏
页码：897 / 902
页数：6
相关论文
共 50 条
  • [21] Management of myelofibrosis after ruxolitinib failure
    Claire N Harrison
    Nicolaas Schaap
    Ruben A Mesa
    Annals of Hematology, 2020, 99 : 1177 - 1191
  • [22] JAK Inhibitors and myelofibrosis, Einstein and ruxolitinib
    Harrison, Claire
    HAEMATOLOGICA, 2015, 100 (04) : 409 - 411
  • [23] Myelofibrosis Management After Ruxolitinib Failure
    Winton, Elliott F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S12 - S14
  • [24] Clarifying the Use of Ruxolitinib in Patients With Myelofibrosis
    Kremyanskaya, Marina
    Atallah, Ehab L.
    Hoffman, Ronald
    Mascarenhas, John O.
    ONCOLOGY-NEW YORK, 2013, 27 (07): : 706 - 714
  • [25] Recommendations on the use of ruxolitinib for the treatment of myelofibrosis
    Devos, Timothy
    Selleslag, Dominik
    Zachee, Pierre
    Benghiat, Fleur Samantha
    HEMATOLOGY, 2018, 23 (04) : 194 - 200
  • [26] RUXOLITINIB IN PATIENS WITH MYELOFIBROSIS, ROMAGNA EXPERIENCE
    Salvucci, M.
    Cellini, C.
    Castagnari, N.
    Zanchini, R.
    D'Addio, A.
    Tani, M.
    Daghia, G.
    Lucchesi, A.
    Zumaglini, F.
    Giannini, B.
    Bagli, L.
    Sensi, A.
    Zuffa, E.
    HAEMATOLOGICA, 2015, 100 : 107 - 107
  • [27] Pharmacoeconomics of ruxolitinib therapy in patients with myelofibrosis
    Vandewalle, Bjorn
    Andreozzi, Valeska
    Almeida, Joao
    Felix, Jorge
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (04) : 424 - 431
  • [28] Ruxolitinib therapy and telomere length in myelofibrosis
    G Caocci
    M Greco
    G Delogu
    C Secchi
    A Perra
    S Ghiani
    F Orru
    A Vacca
    F Galimi
    G La Nasa
    Blood Cancer Journal, 2016, 6 : e479 - e479
  • [29] Ruxolitinib and survival improvement in patients with myelofibrosis
    Passamonti, F.
    Vannucchi, A. M.
    Cervantes, F.
    Harrison, C.
    Morra, E.
    Kantarjian, H.
    Verstovsek, S.
    LEUKEMIA, 2015, 29 (03) : 739 - 740
  • [30] Management of myelofibrosis after ruxolitinib failure
    Harrison, Claire N.
    Schaap, Nicolaas
    Mesa, Ruben A.
    ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1177 - 1191
12345